279 related articles for article (PubMed ID: 12439856)
21. Terminal antisense oligonucleotide modifications can enhance induced exon skipping.
Gebski BL; Errington SJ; Johnsen RD; Fletcher S; Wilton SD
Neuromuscul Disord; 2005 Oct; 15(9-10):622-9. PubMed ID: 16084084
[TBL] [Abstract][Full Text] [Related]
22. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse.
Mann CJ; Honeyman K; Cheng AJ; Ly T; Lloyd F; Fletcher S; Morgan JE; Partridge TA; Wilton SD
Proc Natl Acad Sci U S A; 2001 Jan; 98(1):42-7. PubMed ID: 11120883
[TBL] [Abstract][Full Text] [Related]
23. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse.
Lu QL; Mann CJ; Lou F; Bou-Gharios G; Morris GE; Xue SA; Fletcher S; Partridge TA; Wilton SD
Nat Med; 2003 Aug; 9(8):1009-14. PubMed ID: 12847521
[TBL] [Abstract][Full Text] [Related]
24. Exon-skipping therapy for Duchenne muscular dystrophy.
Nakamura A; Takeda S
Neuropathology; 2009 Aug; 29(4):494-501. PubMed ID: 19486303
[TBL] [Abstract][Full Text] [Related]
25. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping.
Goyenvalle A; Vulin A; Fougerousse F; Leturcq F; Kaplan JC; Garcia L; Danos O
Science; 2004 Dec; 306(5702):1796-9. PubMed ID: 15528407
[TBL] [Abstract][Full Text] [Related]
26. Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides.
Wilton SD; Lloyd F; Carville K; Fletcher S; Honeyman K; Agrawal S; Kole R
Neuromuscul Disord; 1999 Jul; 9(5):330-8. PubMed ID: 10407856
[TBL] [Abstract][Full Text] [Related]
27. Bubble liposomes and ultrasound exposure improve localized morpholino oligomer delivery into the skeletal muscles of dystrophic mdx mice.
Negishi Y; Ishii Y; Shiono H; Akiyama S; Sekine S; Kojima T; Mayama S; Kikuchi T; Hamano N; Endo-Takahashi Y; Suzuki R; Maruyama K; Aramaki Y
Mol Pharm; 2014 Mar; 11(3):1053-61. PubMed ID: 24433046
[TBL] [Abstract][Full Text] [Related]
28. Exon 51 Skipping Quantification by Digital Droplet PCR in del52hDMD/mdx Mice.
Hiller M; Spitali P; Datson N; Aartsma-Rus A
Methods Mol Biol; 2018; 1828():249-262. PubMed ID: 30171546
[TBL] [Abstract][Full Text] [Related]
29. Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: cocktails and chemistries.
Adams AM; Harding PL; Iversen PL; Coleman C; Fletcher S; Wilton SD
BMC Mol Biol; 2007 Jul; 8():57. PubMed ID: 17601349
[TBL] [Abstract][Full Text] [Related]
30. Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles.
Lu QL; Rabinowitz A; Chen YC; Yokota T; Yin H; Alter J; Jadoon A; Bou-Gharios G; Partridge T
Proc Natl Acad Sci U S A; 2005 Jan; 102(1):198-203. PubMed ID: 15608067
[TBL] [Abstract][Full Text] [Related]
31. Targeted disruption of exon 52 in the mouse dystrophin gene induced muscle degeneration similar to that observed in Duchenne muscular dystrophy.
Araki E; Nakamura K; Nakao K; Kameya S; Kobayashi O; Nonaka I; Kobayashi T; Katsuki M
Biochem Biophys Res Commun; 1997 Sep; 238(2):492-7. PubMed ID: 9299538
[TBL] [Abstract][Full Text] [Related]
32. Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle.
Arechavala-Gomeza V; Graham IR; Popplewell LJ; Adams AM; Aartsma-Rus A; Kinali M; Morgan JE; van Deutekom JC; Wilton SD; Dickson G; Muntoni F
Hum Gene Ther; 2007 Sep; 18(9):798-810. PubMed ID: 17767400
[TBL] [Abstract][Full Text] [Related]
33. Wild-type mouse models to screen antisense oligonucleotides for exon-skipping efficacy in Duchenne muscular dystrophy.
Cao L; Han G; Gu B; Yin H
PLoS One; 2014; 9(11):e111079. PubMed ID: 25365558
[TBL] [Abstract][Full Text] [Related]
34. Antisense Oligonucleotide Treatment in a Humanized Mouse Model of Duchenne Muscular Dystrophy and Highly Sensitive Detection of Dystrophin Using Western Blotting.
Maruyama R; Yokota T
Methods Mol Biol; 2021; 2224():203-214. PubMed ID: 33606217
[TBL] [Abstract][Full Text] [Related]
35. In vivo delivery of naked antisense oligos in aged mdx mice: analysis of dystrophin restoration in skeletal and cardiac muscle.
Vitiello L; Bassi N; Campagnolo P; Zaccariotto E; Occhi G; Malerba A; Pigozzo S; Reggiani C; Ausoni S; Zaglia T; Gamba P; Baroni MD; Ditadi AP
Neuromuscul Disord; 2008 Aug; 18(8):597-605. PubMed ID: 18602263
[TBL] [Abstract][Full Text] [Related]
36. Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice.
Yin H; Lu Q; Wood M
Mol Ther; 2008 Jan; 16(1):38-45. PubMed ID: 17968354
[TBL] [Abstract][Full Text] [Related]
37. Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons.
Aartsma-Rus A; Kaman WE; Weij R; den Dunnen JT; van Ommen GJ; van Deutekom JC
Mol Ther; 2006 Sep; 14(3):401-7. PubMed ID: 16753346
[TBL] [Abstract][Full Text] [Related]
38. DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy.
Gurvich OL; Tuohy TM; Howard MT; Finkel RS; Medne L; Anderson CB; Weiss RB; Wilton SD; Flanigan KM
Ann Neurol; 2008 Jan; 63(1):81-9. PubMed ID: 18059005
[TBL] [Abstract][Full Text] [Related]
39. Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells.
Aartsma-Rus A; Kaman WE; Bremmer-Bout M; Janson AA; den Dunnen JT; van Ommen GJ; van Deutekom JC
Gene Ther; 2004 Sep; 11(18):1391-8. PubMed ID: 15229633
[TBL] [Abstract][Full Text] [Related]
40. Effective exon skipping and dystrophin restoration by 2'-o-methoxyethyl antisense oligonucleotide in dystrophin-deficient mice.
Yang L; Niu H; Gao X; Wang Q; Han G; Cao L; Cai C; Weiler J; Yin H
PLoS One; 2013; 8(4):e61584. PubMed ID: 23658612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]